Related Experiment Videos

Lymphocyte predominant Hodgkin's disease: more patience than patients

Bradley C Ekstrand¹, Sandra J Horning

¹Department of Medicine, Stanford University School of Medicine, California 94304, USA.

Cancer Journal (Sudbury, Mass.)

|November 6, 2002

Abstract

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Incorporation of extracorporeal photopheresis into a reduced intensity conditioning regimen in myelodysplastic syndrome and aggressive lymphoma: results from ECOG 1402 and 1902.

Transfusion·2020

Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab.

Journal for immunotherapy of cancer·2019

Randomized phase 3 study in low-grade lymphoma comparing maintenance anti-CD20 antibody with observation after induction therapy: A trial of the ECOG-ACRIN Cancer Research Group (E1496).

Cancer·2016

Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402.

British journal of haematology·2016

Fc Gamma Receptor 3A and 2A Polymorphisms Do Not Predict Response to Rituximab in Follicular Lymphoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2015

Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era.

British journal of haematology·2015

See all related articles